EN

ENZYCHEM LIFESCIENCES CORPORATION

Develops novel therapeutics and APIs for oncology, inflammation, and respiratory diseases.

183490 | KO

Overview

Corporate Details

ISIN(s):
KR7183490002
LEI:
Country:
South Korea
Address:
충청북도 제천시 바이오밸리로 59, 제천시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Enzychem Lifesciences Corporation is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics for inflammatory diseases, oncology, and severe respiratory conditions. The company's primary focus is its lead candidate, EC-18 (Mosedipimod), an oral immunomodulator designed to target fundamental inflammation pathways. Its development pipeline addresses significant unmet medical needs, including chemoradiation-induced oral mucositis (CRIOM), chemotherapy-induced neutropenia (CIN), and acute radiation syndrome (ARS). In addition to its research and development in new drugs, the company also develops and manufactures Active Pharmaceutical Ingredients (APIs).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-20 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득신탁계약체결결정)
Korean 33.2 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.9 MB
2025-06-10 00:00
Transaction in Own Shares
신탁계약해지결과보고서
Korean 21.5 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.7 MB
2025-04-21 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 93.4 KB
2025-04-08 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 95.3 KB
2025-03-26 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 26.9 KB
2025-03-24 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 95.3 KB
2025-03-18 00:00
Audit Report / Information
감사보고서제출
Korean 26.3 KB
2025-03-18 00:00
Annual Report
사업보고서 (2024.12)
Korean 2.5 MB
2025-03-12 00:00
Major Shareholding Notification
신탁계약에의한취득상황보고서
Korean 49.5 KB
2025-03-07 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 264.6 KB
2025-03-07 00:00
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
Korean 216.5 KB
2025-03-06 00:00
Earnings Release
[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 18.8 KB
2025-03-05 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 15.3 KB

Automate Your Workflow. Get a real-time feed of all ENZYCHEM LIFESCIENCES CORPORATION filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ENZYCHEM LIFESCIENCES CORPORATION

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ENZYCHEM LIFESCIENCES CORPORATION via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Tourmaline Bio, Inc. Logo
Develops an anti-IL-6 antibody for cardiovascular, inflammatory, and immune diseases.
United States of America
TRML
TOWA PHARMACEUTICAL CO.,LTD. Logo
Manufactures and markets high-quality, accessible generic drugs for various therapeutic areas.
Japan
4553
Transcode Therapeutics, Inc. Logo
Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.
United States of America
RNAZ
Travere Therapeutics, Inc. Logo
Develops therapies for rare kidney and metabolic diseases, with an FDA-approved treatment for IgA nephropathy.
United States of America
TVTX
Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW
TScan Therapeutics, Inc. Logo
Developing TCR-engineered T-cell therapies for solid and hematologic cancers.
United States of America
TCRX
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan
4540
TuHURA Biosciences, Inc./NV Logo
Phase 3 immuno-oncology firm developing therapeutics to overcome cancer therapy resistance.
United States of America
HURA
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye
TRILC
Tvardi Therapeutics, Inc. Logo
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
United States of America
TVRD

Talk to a Data Expert

Have a question? We'll get back to you promptly.